What VERTEX PHARMACEUTICALS INC / MA's SEC filings said

10-Q for 2026Q3, filed 3 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Operating Expense Trends77 · importance in its document · 10-Q · 2026Q3
Research and development expense increased 35% to $1,320.6 million in the third quarter and 12% to $3,276.0 million in the first nine months of 2026.,Development expense rose 42% to $1,091.6 million in the third quarter, including $235.3 million of compensation for cash-settled unvested Crinetics equity awards and higher outsourced services and other direct expenses.,Selling, general and administrative expense increased 90% to $844.1 million in the third quarter and 52% to $1,920.0 million in the first nine months, including $203.0 million of Crinetics-related compensation and transaction costs.,The company also cited increased headcount and commercial investment for JOURNAVX and the anticipated povetacicept IgAN launch; nine-month AIPR&D declined 18% to $62.5 million.
Liquidity and Debt Position73 · importance in its document · 10-Q · 2026Q3
Cash, cash equivalents and marketable securities totaled $9,821.2 million at September 30, 2026, down 20% from $12,320.4 million at December 31, 2025, primarily following the Crinetics acquisition and share repurchases.,Working capital decreased 9% to $6,686.0 million, reflecting $1.0 billion of short-term debt and lower cash and short-term securities, partly offset by acquired inventory.,Vertex borrowed the full $4.5 billion under its 2026 Term Loan in September; repayment is scheduled as $1.0 billion in August 2027, $1.0 billion in September 2028 and $2.5 billion in August 2029.,Operating cash flow was $3,196.6 million in the first nine months of 2026, while investing cash flow used $6,578.3 million and financing cash flow provided $3,331.4 million; Vertex said available funds and operating cash flows are expected to fund operations for at least 12 months.
CASGEVY Pediatric Market Expansion72 · importance in its document · 10-Q · 2026Q3
CASGEVY generated $99.2 million in third-quarter 2026 product revenue, up 30% from the second quarter and more than 400% year over year. The FDA approved CASGEVY for children aged two and older with sickle cell disease (SCD) or…
Acquisition / Partnership / Divestiture71 · importance in its document · 10-Q · 2026Q3
Vertex completed its acquisition of Crinetics in September 2026 for $85.00 per share in cash, representing $10.0 billion of equity value and $9.0 billion net of acquired cash, cash equivalents and marketable securities.,Vertex financed the acquisition using cash and marketable securities plus $4.5 billion borrowed under the 2026 Term Loan.,The business combination added $8.1 billion of intangible assets to the balance sheet and brought PALSONIFY into Vertex's commercial portfolio.,Vertex recorded $62.5 million of AIPR&D in the first nine months of 2026, including upfront, contingent milestone or other payments under business development transactions.

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 3 Nov 2026

Full report · Filing on EDGAR

Operating Expense TrendsImportance 77
Research and development expense increased 35% to $1,320.6 million in the third quarter and 12% to $3,276.0 million in the first nine months of 2026.,Development expense rose 42% to $1,091.6 million in the third quarter, including $235.3 million of compensation for cash-settled unvested Crinetics equity awards and higher outsourced services and other direct expenses.,Selling, general and administrative expense increased 90% to $844.1 million in the third quarter and 52% to $1,920.0 million in the first nine months, including $203.0 million of Crinetics-related compensation and transaction costs.,The company also cited increased headcount and commercial investment for JOURNAVX and the anticipated povetacicept IgAN launch; nine-month AIPR&D declined 18% to $62.5 million.
Liquidity and Debt PositionImportance 73
Cash, cash equivalents and marketable securities totaled $9,821.2 million at September 30, 2026, down 20% from $12,320.4 million at December 31, 2025, primarily following the Crinetics acquisition and share repurchases.,Working capital decreased 9% to $6,686.0 million, reflecting $1.0 billion of short-term debt and lower cash and short-term securities, partly offset by acquired inventory.,Vertex borrowed the full $4.5 billion under its 2026 Term Loan in September; repayment is scheduled as $1.0 billion in August 2027, $1.0 billion in September 2028 and $2.5 billion in August 2029.,Operating cash flow was $3,196.6 million in the first nine months of 2026, while investing cash flow used $6,578.3 million and financing cash flow provided $3,331.4 million; Vertex said available funds and operating cash flows are expected to fund operations for at least 12 months.
CASGEVY Pediatric Market ExpansionImportance 72
CASGEVY generated $99.2 million in third-quarter 2026 product revenue, up 30% from the second quarter and more than 400% year over year. The FDA approved CASGEVY for children aged two and older with sickle cell disease…
Acquisition / Partnership / DivestitureImportance 71 · +1 more on this subject
Vertex completed its acquisition of Crinetics in September 2026 for $85.00 per share in cash, representing $10.0 billion of equity value and $9.0 billion net of acquired cash, cash equivalents and marketable securities.,Vertex financed the acquisition using cash and marketable securities plus $4.5 billion borrowed under the 2026 Term Loan.,The business combination added $8.1 billion of intangible assets to the balance sheet and brought PALSONIFY into Vertex's commercial portfolio.,Vertex recorded $62.5 million of AIPR&D in the first nine months of 2026, including upfront, contingent milestone or other payments under business development transactions.
Market Demand TrendsImportance 60 · +1 more on this subject
Vertex reported continued growth in cystic fibrosis (CF) therapies and expanding contributions from CASGEVY, JOURNAVX, and PALSONIFY, with total product revenues up 11% in the first nine months of 2026. CF remains the…
Geographic Market CommentaryImportance 57
In the first nine months of 2026, U.S. total revenue increased 9%, supported by strong patient demand, new ALYFTREK initiations, higher realized net prices in CF, and contributions from CASGEVY, JOURNAVX, and…
Revenue Performance and MixImportance 54
Third-quarter 2026 total revenue was $3,440.8 million, up 12% from $3,076.4 million, while nine-month revenue rose 11% to $9,761.6 million from $8,811.3 million.,Nine-month CF product revenue increased 8% to $9,396.1 million; ALYFTREK revenue grew 272% to $1,703.8 million, offsetting a 6% decline in TRIKAFTA/KAFTRIO to $7,288.8 million and a 17% decline in other CF products to $403.5 million.,Nine-month CASGEVY revenue increased 255% to $218.5 million and JOURNAVX revenue increased 316% to $136.9 million, while PALSONIFY contributed $10.1 million following the September 1, 2026 Crinetics acquisition.,U.S. revenue increased 9% to $6,001.4 million in the first nine months, and ex-U.S. revenue increased 13% to $3,760.2 million, with ex-U.S. growth also benefiting from favorable foreign exchange.
Gross Margin DriversImportance 54
Cost of sales was $526.1 million in the third quarter of 2026, up 27% year over year, and $1,408.1 million for the first nine months, up 19%.,Cost of sales rose to 15.3% of net product revenue in the third quarter and 14.4% for the first nine months, compared with 13.5% in each 2025 period.,The higher cost ratio reflected product mix and Crinetics-related PALSONIFY amortization of $15.3 million and acquired inventory step-up expense of $5.4 million for September, partly offset by lower blended CF royalty rates.,Management said PALSONIFY amortization and acquired inventory step-up expenses will increase in future quarters.
Povetacicept Regulatory ReviewImportance 47 · +1 more on this subject
The FDA placed Vertex’s biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy (IgAN) under priority review, with a target action date of November 30, 2026. If approved,…
ALYFTREK Royalty ArbitrationImportance 40
On October 10, 2025, Royalty Pharma and the Cystic Fibrosis Foundation initiated confidential arbitration over royalties on ALYFTREK sales. Vertex maintains that the royalty burden is 4%, while the claimants allege it…
PALSONIFY Market AdoptionImportance 34
PALSONIFY is a once-daily oral treatment approved in the U.S. for adults with acromegaly who had an inadequate response to surgery or cannot undergo surgery; Vertex estimates it is an option for 12,000 U.S. adults.…
IgAN Launch and DifferentiationImportance 34
Vertex is preparing for a potential launch of povetacicept for IgA nephropathy (IgAN), positioning it as a potentially best-in-class dual inhibitor of BAFF and APRIL cytokines to control B-cell activity. The biologics…

8-K filings last 12 months

Results, no stated guidance change2 Nov 2026 · 8-K Item 2.02 · Routine · rule score 10
Read from the attached exhibit: Operating Expense Trends · Acquisition / Partnership / Divestiture · Liquidity and Debt Position
Board change20 Oct 2026 · 8-K Item 5.02 · Routine · rule score 10
“Departure of Directors of Directors or Certain Officers;”
CFO exit1 Sept 2026 · 8-K Item 5.02 · Flagged · rule score 55
“In connection with Mr. Poole’s appointment, Charles F. Wagner, Jr., the Company’s Executive Vice President and Chief Operating & Financial Officer, will cease serving as Chief Financial Officer as of the Effective Date, but will remain…”
Results (release not read)3 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
Read from the attached exhibit: Product Launch and Transition · Guidance / Outlook · CASGEVY Pediatric Market Expansion
Agreement to be acquired7 Jul 2026 · 8-K Item 1.01 · Flagged · rule score 95
“On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Crinetics Pharmaceuticals, Inc.,…”
Read from the attached exhibit: Acquisition / Partnership / Divestiture · Guidance / Outlook · Product / Drug Pipeline Progress
Other officer change13 May 2026 · 8-K Item 5.02 · Routine · rule score 15
“Departure of Directors of Directors or Certain Officers;”
Guidance reaffirmed4 May 2026 · 8-K Item 2.02 · Routine · rule score 15
“The increase was primarily due to cash flows from operating activities, partially offset by repurchases of Vertex’s common stock pursuant to its share repurchase programs. 2 Full Year 2026 Financial Guidance Vertex today reiterated full…”
Other officer change29 Apr 2026 · 8-K Item 5.02 · Routine · rule score 15
“Mr. Upadhyay has recently been named the forthcoming Chief Financial Officer of Incyte Corporation.”
Results (release not read)12 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

10-Q · 2026Q2filed 4 Aug 2026
End-Market Demand Trends · Operating Expense Trends · Crinetics Acquisition Financing

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.